LONDON, July 28, 2016 /PRNewswire/ -- Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announces the first surgical case of its robotics-assisted total knee replacement procedure. The new approach, which recently received 510(k) clearance from the US Food and Drug Administration, uses the NAVIO Surgical System to implant the JOURNEY™ II BCS and CR total knee systems.
The surgery was performed by Dr. Brian McGinley at the John T. Mather Memorial Hospital in Port Jefferson, NY. Dr. McGinley commented: "The handheld robotics-assisted NAVIO platform provided me a precise and efficient placement of the JOURNEY II BCS. I was delighted to see how seamlessly it integrated into our workflow."
During a total knee replacement surgery, the NAVIO system is designed to deliver consistent and accurate results through the utilization of a robotics-assisted hand piece, navigation and NAVIO specific cut guides, all of which enable better patient outcomes. The NAVIO intra-operative planning software uses 3D surface capture to predict joint laxity, enable precise implant positioning, and customize a solution for each patient. Unlike other robotics-assisted platforms, the NAVIO system does not require a pre-operative CT scan.
While Smith & Nephew's JOURNEY PFJ, JOURNEY UNI, STRIDE™ and ZUK partial knee systems have been widely available for use with the NAVIO system, this milestone marks the first time orthopaedic surgeons will have access to the robotics-assisted technology when implanting the company's total knee systems. Currently available for the JOURNEY II total knee system, additional total knee systems are expected to be supported by the NAVIO system in future releases.
"We're excited to introduce the combination of our NAVIO Surgical System and the JOURNEY II total knee system to the orthopaedic community," said Mike Donoghue, Senior Vice President of Global Marketing for Orthopaedics at Smith & Nephew. "Surgeons now have access to a highly portable, robotics-assisted technique that marks the next step in Smith & Nephew's pioneering approach to joint reconstruction. This cost-effective procedure positions us particularly well in the US market, where bundled payments and ambulatory surgery centers have shifted focus to the economic feasibility and overall value of new technology for joint replacement procedures."
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN,NYSE:SNN).
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew